Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTS-2096
- Development stage
- Preclinical
- Lead developer
- Histogen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CTS-2096 is a preclinical, orally bioavailable small‑molecule inhibitor of caspase‑1 being developed by Histogen for inflammatory indications driven by inflammasome activation.[1][3][5][6][9] It is described as a novel, potent, and highly selective caspase‑1 inhibitor and inflammasome pathway inhibitor, designed to reduce maturation and release of pro‑inflammatory cytokines such as interleukin‑1β (IL‑1β) and downstream inflammatory cell death processes, with the goal of treating a range of inflammatory diseases.[1][3][5][6][9]
02
Targets
CASP1 (Caspase-1)
Beyond the preview
Go deeper on CTS-2096.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTS-2096.